Results 1 to 10 of about 16,070 (135)
American Journal of Neuroradiology, 2011 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
L, Murphy, L, Lawler, E C, Kavanagh
openaire +3 more sources
Cells, 2021 Dabigatran is a novel oral anticoagulant that directly inhibits free and fibrin-bound thrombins and exerts rapid and predictable anticoagulant effects. While the use of this reagent has been associated with an increased risk of gastrointestinal bleeding,
Hiromi Kurokawa +3 more
doaj +1 more source
Pharmaceuticals, 2023 Higher risk of major hemorrhage associated with concomitant use of dabigatran and simvastatin compared to other statins was previously reported with a suggestion of P-glycoprotein-mediated interaction. The aim of this study was to evaluate the effects of
Hyewon Chung +5 more
doaj +1 more source
Dabigatran: Clinical correlation of drug and its dose with risk of stroke and bleeding
Perspectives in Clinical Research, 2023 Background: Dabigatran is the first oral direct thrombin inhibitor which is endorsed by Food and Drug Administration in the prevention of embolic events in patients with nonvalvular atrial fibrillation.
Anitta Shaji +4 more
doaj +1 more source
Pharmacokinetics and Pharmacogenetics of Dabigatran
Рациональная фармакотерапия в кардиологии, 2021 Dabigatran etexilate is a prodrug of dabigatran, a oral direct inhibitor of thrombin. Pharmacokinetics of dabigatran etexilate doesn’t have the disadvantages of vitamin K antagonists.
A. V. Savinova +4 more
doaj +1 more source
American Journal of Neuroradiology, 2012 Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less ...
J, Comin, D F, Kallmes
openaire +2 more sources
The preoperative management of dabigatran and its specific antidote idarucizumab in patients with nonvalvular atrial fibrillation: Case reports [PDF]
Arhiv za farmaciju, 2020 Dabigatran is a novel oral anticoagulant preferred due to its ease of use, favorable pharmacokinetics, decreased potential for drug-drug interactions, and the lack of monitoring requirements.
Tomić Milan
doaj +1 more source
Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran [PDF]
Pharmaceutics, 2022 Dabigatran (DAB) is an orally administered thrombin inhibitor. Both DAB and its main metabolite dabigatran acylglucuronide (DABG) have established anticoagulant effects. Here, we aimed to compare the relative anticoagulant effects of DABG and DAB in humans.
Jong-Min Kim +7 more
openaire +3 more sources
Dabigatran in Cerebral Sinus Vein Thrombosis and Thrombophilia
Life, 2022 Background and Purpose: Thrombophilic gene alterations are a major risk factor for cerebral sinus vein thrombosis (CSVT). Up to 30% of all patients with cerebral sinus vein thrombosis (CSVT) are found to have thrombophilic defects such as prothrombin ...
Lukas Kellermair +5 more
doaj +1 more source
Impact of Dabigatran Treatment on Rotation Thromboelastometry
Clinical and Applied Thrombosis/Hemostasis, 2021 A rapid and reliable assessment of the dabigatran effect is desirable in dabigatran treated patients with uncontrolled bleeding or before acute surgery.
Juraj Sokol MD, PhD +8 more
doaj +1 more source